StockData

Aytu BioPharma vs Ocular Therapeutix

AYTU and OCUL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AYTU and OCUL compare

Ocular Therapeutix is the larger company, worth 71 times as much as Aytu BioPharma ($1.4B against $19.3M).

Ocular Therapeutix grew revenue faster over the last twelve months (−9.7% versus −13.3% for Aytu BioPharma).

Aytu BioPharma keeps more of each dollar of sales as profit, with a net margin of −24.8% compared with −649% at Ocular Therapeutix.

Aytu BioPharma scores higher on the StockData Score (9 against 3 for Ocular Therapeutix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAYTUOCUL
Size and price
Market cap$19.3M$1.4B
Share price$1.78$6.21
Change, 1 year−13.6%−46.0%
Change, 5 years−95.6%−7.2%
Beta (5Y)1.051.25
Employees76325
StockData Score
Total score9 (better)3
Valuation score3 (better)0
Growth score00
Performance score3 (better)0
Health score33
Dividend score00
Valuation
P/S0.3× (better)27.1×
P/B0.5× (better)3.1×
P/FCF5.9×–
FCF yield16.8% (better)−19.6%
Fair value$8.51$4.70
Margin of safety79.1% (better)−32.2%
Growth
Revenue growth (TTM)−13.3%−9.7% (better)
Revenue growth, 5Y average−2.6%24.4% (better)
Profitability
Gross margin64.0%87.3% (better)
Operating margin−14.4% (better)−681%
Net margin−24.8% (better)−649%
FCF margin5.6% (better)−530%
Return on equity−52.6% (better)−93.5%
Return on invested capital−63.5%–
Financial health
Debt / equity0.310.17 (better)
Interest coverage−4.4× (better)−30.6×
Current ratio1.139.12 (better)
Altman Z-score−4.100.92 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions45.3%94.4%
Held by insiders15.1%2.9%
Insider net buying, 12 months–−$2.5M
Short interest, % of float3.3%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.